Orchestra BioMed Holdings Key Executives
This section highlights Orchestra BioMed Holdings's key executives, including their titles and compensation details.
Find Contacts at Orchestra BioMed Holdings
(Showing 0 of )
Orchestra BioMed Holdings Earnings
This section highlights Orchestra BioMed Holdings's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
$3.83
Stock Price
$145.65M
Market Cap
70
Employees
New Hope, PA
Location
Financial Statements
Access annual & quarterly financial statements for Orchestra BioMed Holdings, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $2.64M | $2.76M | $3.53M | $-782.00K | $5.70M |
| Cost of Revenue | $204.00K | $186.00K | $322.00K | $199.00K | $145.00K |
| Gross Profit | $2.43M | $2.57M | $3.21M | $-981.00K | $5.56M |
| Gross Profit Ratio | 92.27% | 93.26% | 90.89% | 125.40% | 97.46% |
| Research and Development Expenses | $42.80M | $33.82M | $21.95M | $12.89M | $13.48M |
| General and Administrative Expenses | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $23.93M | $20.26M | $13.92M | $7.93M | $10.83M |
| Other Expenses | $- | $- | $- | $- | $- |
| Operating Expenses | $66.73M | $54.08M | $35.87M | $20.82M | $24.31M |
| Cost and Expenses | $66.94M | $54.27M | $36.19M | $21.02M | $24.45M |
| Interest Income | $- | $3.85M | $50.00K | $927.00K | $331.00K |
| Interest Expense | $- | $- | $- | $927.00K | $- |
| Depreciation and Amortization | $- | $287.00K | $222.00K | $181.00K | $137.00K |
| EBITDA | $-64.30M | $-51.22M | $-32.44M | $-21.62M | $-18.61M |
| EBITDA Ratio | -2437.49% | -1855.76% | -918.06% | 2764.45% | -274.96% |
| Operating Income | $-64.30M | $-51.51M | $-32.66M | $-21.80M | $-18.75M |
| Operating Income Ratio | -2437.49% | -1866.16% | -924.34% | 2787.60% | -328.81% |
| Total Other Income Expenses Net | $3.28M | $2.39M | $-951.00K | $-1.22M | $-2.60M |
| Income Before Tax | $-61.02M | $-49.12M | $-33.61M | $-23.01M | $-21.36M |
| Income Before Tax Ratio | -2313.27% | -1779.71% | -951.26% | 2942.97% | -374.45% |
| Income Tax Expense | $- | $- | $-222.00K | $927.00K | $2.60M |
| Net Income | $-61.02M | $-49.12M | $-33.61M | $-23.01M | $-21.36M |
| Net Income Ratio | -2313.27% | -1779.71% | -951.26% | 2942.97% | -374.45% |
| EPS | $0.00 | $-1.48 | $-2.24 | $-1.13 | $-1.04 |
| EPS Diluted | $0.00 | $-1.48 | $-2.24 | $-1.13 | $-1.04 |
| Weighted Average Shares Outstanding | 36.82B | 33.23M | 14.99M | 20.45M | 20.45M |
| Weighted Average Shares Outstanding Diluted | 36.82B | 33.23M | 14.99M | 20.45M | 20.45M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $253.00K | $987.00K | $778.00K | $620.00K | $262.00K | $419.00K | $915.00K | $1.16M | $1.10M | $1.16M | $401.00K | $866.00K | $-2.45M | $1.33M | $-978.00K | $1.32M |
| Cost of Revenue | $-16.00K | $68.00K | $44.00K | $108.00K | $83.00K | $41.00K | $54.00K | $44.00K | $53.00K | $56.00K | $60.00K | $42.00K | $58.00K | $44.00K | $62.00K | $35.00K |
| Gross Profit | $269.00K | $919.00K | $734.00K | $512.00K | $179.00K | $378.00K | $861.00K | $1.12M | $1.05M | $1.11M | $341.00K | $824.00K | $-2.51M | $1.29M | $-1.04M | $1.28M |
| Gross Profit Ratio | 106.32% | 93.11% | 94.30% | 82.60% | 68.30% | 90.20% | 94.10% | 96.20% | 95.20% | 95.20% | 85.00% | 95.20% | 102.40% | 96.70% | 106.30% | 97.30% |
| Research and Development Expenses | $10.97M | $11.60M | $11.13M | $9.11M | $8.51M | $8.56M | $8.50M | $8.25M | $7.54M | $5.90M | $5.03M | $3.47M | $3.53M | $3.66M | $2.64M | $3.06M |
| General and Administrative Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $5.97M | $5.67M | $6.47M | $5.82M | $4.15M | $6.34M | $5.32M | $4.41M | $876.72K | $813.41K | $2.95M | $2.48M | $92.05K | $94.44K | $96.32K | $111.95K |
| Other Expenses | $- | $- | $- | $-11.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Operating Expenses | $16.95M | $17.26M | $17.59M | $14.94M | $12.66M | $14.90M | $13.82M | $12.66M | $876.72K | $813.41K | $7.97M | $5.95M | $92.05K | $94.44K | $96.32K | $111.95K |
| Cost and Expenses | $16.93M | $17.33M | $17.64M | $15.04M | $12.74M | $14.94M | $13.87M | $12.71M | $876.72K | $813.41K | $8.04M | $5.99M | $92.05K | $94.44K | $96.32K | $111.95K |
| Interest Income | $-2.83M | $916.00K | $902.00K | $1.02M | $1.11M | $915.00K | $941.00K | $1.24M | $469.00K | $127.62K | $- | $- | $249.00K | $184.00K | $294.00K | $200.00K |
| Interest Expense | $- | $- | $- | $- | $- | $- | $- | $351.00K | $- | $- | $246.00K | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $-224.00K | $76.00K | $74.00K | $74.00K | $72.00K | $71.00K | $231.00K | $226.00K | $70.00K | $54.00K | $50.00K | $48.00K | $48.00K | $46.00K | $44.00K | $43.00K |
| EBITDA | $-16.41M | $-16.27M | $-16.79M | $-14.35M | $-12.41M | $-14.45M | $-12.88M | $-11.47M | $-9.76M | $-10.01M | $-7.58M | $-5.08M | $-7.86M | $-4.34M | $-5.54M | $-3.88M |
| EBITDA Ratio | -6486.06% | -1648.02% | -2157.46% | -2314.35% | -4736.26% | -3519.33% | -1404.59% | -961.68% | -79.49% | -69.94% | -1982.29% | -544.46% | 3.75% | -7.08% | 9.85% | -8.51% |
| Operating Income | $-16.68M | $-16.34M | $-16.86M | $-14.42M | $-12.48M | $-14.52M | $-12.96M | $-11.54M | $-876.72K | $-813.42K | $-7.63M | $-5.13M | $-92.04K | $-94.44K | $-96.32K | $-111.95K |
| Operating Income Ratio | -6591.70% | -1655.72% | -2166.97% | -2326.29% | -4763.74% | -3466.35% | -1415.96% | -991.84% | -79.49% | -69.94% | -1903.74% | -592.15% | 3.75% | -7.08% | 9.85% | -8.51% |
| Total Other Income Expenses Net | $522.00K | $916.00K | $879.00K | $960.00K | $-337.00K | $1.21M | $910.00K | $605.00K | $78.00K | $-215.00K | $-213.00K | $-601.00K | $4.03K | $4.03K | $3.99K | $3.95K |
| Income Before Tax | $-16.16M | $-15.43M | $-15.98M | $-13.46M | $-12.82M | $-13.32M | $-12.05M | $-10.94M | $-876.72K | $-685.79K | $-7.85M | $-5.73M | $-88.01K | $-90.41K | $-92.33K | $-108.00K |
| Income Before Tax Ratio | -6385.38% | -1562.92% | -2053.98% | -2171.45% | -4892.37% | -3178.04% | -1316.50% | -939.86% | -79.49% | -58.97% | -1956.86% | -661.55% | 3.59% | -6.78% | 9.44% | -8.21% |
| Income Tax Expense | $-30.72K | $- | $- | $30.72K | $2.72M | $-1.21M | $-910.00K | $-605.00K | $-70.00K | $-54.00K | $-119.00K | $601.00K | $-48.00K | $-46.00K | $-44.00K | $-43.00K |
| Net Income | $-16.16M | $-15.43M | $-15.98M | $-13.46M | $-12.82M | $-13.32M | $-12.05M | $-10.94M | $-876.72K | $-685.79K | $-7.85M | $-5.73M | $-88.01K | $-90.41K | $-92.33K | $-108.00K |
| Net Income Ratio | -6385.38% | -1562.92% | -2053.98% | -2171.45% | -4892.37% | -3178.04% | -1316.50% | -939.86% | -79.49% | -58.97% | -1956.86% | -661.55% | 3.59% | -6.78% | 9.44% | -8.21% |
| EPS | $1.22 | $-0.41 | $-0.45 | $-0.38 | $-0.36 | $-0.38 | $-0.35 | $-0.40 | $-0.08 | $-0.05 | $-0.25 | $-0.18 | $0.00 | $0.00 | $0.00 | $-0.01 |
| EPS Diluted | $1.22 | $-0.41 | $-0.45 | $-0.38 | $-0.36 | $-0.38 | $-0.35 | $-0.40 | $-0.08 | $-0.05 | $-0.25 | $-0.18 | $0.00 | $0.00 | $0.00 | $-0.01 |
| Weighted Average Shares Outstanding | 36.82M | 37.62M | 35.80M | 35.78M | 35.78M | 35.24M | 34.61M | 27.64M | 11.21M | 13.72M | 31.61M | 31.61M | 20.45M | 20.45M | 20.45M | 20.45M |
| Weighted Average Shares Outstanding Diluted | 36.82M | 37.62M | 35.80M | 35.78M | 35.78M | 35.24M | 34.61M | 27.64M | 11.21M | 13.72M | 31.61M | 31.61M | 20.45M | 20.45M | 20.45M | 20.45M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $22.26M | $30.56M | $19.78M | $9.94M | $20.34M |
| Short Term Investments | $44.55M | $57.04M | $64.00M | $958.00K | $15.45M |
| Cash and Short Term Investments | $66.81M | $87.59M | $83.78M | $10.90M | $35.79M |
| Net Receivables | $92.00K | $99.00K | $96.00K | $121.00K | $168.00K |
| Inventory | $173.00K | $146.00K | $276.00K | $68.00K | $69.00K |
| Other Current Assets | $2.09M | $1.27M | $533.00K | $234.00K | $227.00K |
| Total Current Assets | $69.17M | $89.11M | $84.69M | $11.32M | $36.25M |
| Property Plant Equipment Net | $3.49M | $2.83M | $3.68M | $1.12M | $1.03M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $2.50M | $2.50M | $2.50M | $398.00K | $185.00K |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $1.02M | $769.00K | $4.71M | $690.00K | $626.00K |
| Total Non-Current Assets | $7.00M | $6.10M | $10.88M | $2.21M | $1.84M |
| Other Assets | $- | $- | $- | $- | $- |
| Total Assets | $76.17M | $95.21M | $95.57M | $13.53M | $38.09M |
| Account Payables | $5.13M | $2.90M | $3.97M | $2.03M | $1.77M |
| Short Term Debt | $550.00K | $649.00K | $697.00K | $2.00M | $4.00M |
| Tax Payables | $- | $- | $- | $1.00K | $67.00K |
| Deferred Revenue | $4.44M | $2.51M | $6.44M | $5.54M | $5.80M |
| Other Current Liabilities | $6.08M | $5.15M | $7.46M | $8.21M | $8.52M |
| Total Current Liabilities | $16.21M | $11.21M | $18.57M | $12.24M | $14.36M |
| Long Term Debt | $1.69M | $1.04M | $11.17M | $3.67M | $5.46M |
| Deferred Revenue Non-Current | $- | $14.92M | $13.10M | $16.86M | $15.12M |
| Deferred Tax Liabilities Non-Current | $- | $- | $1.68M | $51.45M | $51.45M |
| Other Non-Current Liabilities | $25.32M | $- | $196.00K | $-34.06M | $-36.09M |
| Total Non-Current Liabilities | $27.01M | $15.96M | $24.47M | $72.52M | $72.27M |
| Other Liabilities | $- | $- | $1 | $- | $- |
| Total Liabilities | $43.22M | $27.17M | $43.04M | $84.76M | $86.63M |
| Preferred Stock | $- | $- | $51.45M | $51.45M | $51.45M |
| Common Stock | $4.00K | $4.00K | $2.00K | $160.00M | $160.00M |
| Retained Earnings | $-309.88M | $-248.85M | $-199.73M | $-166.13M | $-143.11M |
| Accumulated Other Comprehensive Income Loss | $52.00K | $-10.00K | $-8.00K | $-211.45M | $-2.00K |
| Other Total Stockholders Equity | $342.78M | $316.90M | $252.27M | $357.80M | $146.02M |
| Total Stockholders Equity | $32.96M | $68.04M | $52.53M | $-71.23M | $-48.54M |
| Total Equity | $32.96M | $68.04M | $52.53M | $-71.23M | $-48.54M |
| Total Liabilities and Stockholders Equity | $76.17M | $95.21M | $95.57M | $13.53M | $38.09M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $76.17M | $95.21M | $95.57M | $13.53M | $38.09M |
| Total Investments | $47.05M | $59.53M | $66.50M | $1.36M | $15.63M |
| Total Debt | $2.24M | $1.69M | $11.87M | $5.67M | $9.46M |
| Net Debt | $-20.02M | $-28.87M | $-7.91M | $-4.26M | $-10.89M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $22.26M | $25.61M | $23.71M | $23.32M | $30.56M | $19.08M | $16.41M | $18.70M | $175.16K | $735.22K | $106.97M | $1.42M | $9.94M | $1.78M | $1.91M | $1.95M |
| Short Term Investments | $44.55M | $41.32M | $41.47M | $51.71M | $57.04M | $89.77M | $101.36M | $108.54M | $64.00M | $251.00K | $579.00K | $738.00K | $958.00K | $- | $- | $- |
| Cash and Short Term Investments | $66.81M | $66.93M | $65.18M | $75.04M | $87.59M | $108.85M | $117.77M | $127.23M | $175.16K | $735.22K | $107.55M | $1.42M | $10.90M | $1.78M | $1.91M | $1.95M |
| Net Receivables | $92.00K | $115.00K | $80.00K | $67.00K | $99.00K | $86.00K | $171.00K | $76.00K | $96.00K | $96.00K | $80.00K | $79.00K | $121.00K | $- | $- | $- |
| Inventory | $173.00K | $234.00K | $70.00K | $115.00K | $146.00K | $137.00K | $178.00K | $232.00K | $276.00K | $330.00K | $133.00K | $32.00K | $68.00K | $- | $- | $- |
| Other Current Assets | $2.09M | $1.28M | $1.15M | $1.21M | $1.27M | $1.12M | $1.47M | $2.34M | $533.00K | $-288.66K | $837.00K | $-39.71K | $234.00K | $81.17K | $105.67K | $142.41K |
| Total Current Assets | $69.17M | $68.55M | $66.48M | $76.43M | $89.11M | $110.19M | $119.59M | $129.88M | $299.08K | $872.55K | $108.60M | $1.49M | $11.32M | $1.86M | $2.02M | $2.09M |
| Property Plant Equipment Net | $3.49M | $2.97M | $2.57M | $2.81M | $2.83M | $3.07M | $3.28M | $3.48M | $3.68M | $3.84M | $3.82M | $3.60M | $1.12M | $- | $- | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $2.50M | $2.50M | $2.50M | $2.50M | $2.50M | $2.50M | $2.50M | $2.50M | $67.78M | $67.78M | $2.50M | $160.04M | $398.00K | $160.02M | $160.01M | $160.01M |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $1.02M | $1.30M | $841.00K | $894.00K | $769.00K | $604.00K | $517.00K | $421.00K | $-3.68M | $-3.84M | $2.19M | $-3.60M | $690.00K | $- | $- | $- |
| Total Non-Current Assets | $7.00M | $6.77M | $5.90M | $6.20M | $6.10M | $6.17M | $6.29M | $6.40M | $67.78M | $67.78M | $8.51M | $160.04M | $2.21M | $160.02M | $160.01M | $160.01M |
| Other Assets | $- | $- | $1 | $1 | $1 | $- | $- | $- | $1 | $1 | $- | $- | $- | $- | $- | $1 |
| Total Assets | $76.17M | $75.32M | $72.38M | $82.63M | $95.21M | $116.36M | $125.88M | $136.28M | $68.08M | $68.65M | $117.11M | $161.53M | $13.53M | $161.88M | $162.03M | $162.10M |
| Account Payables | $5.13M | $4.72M | $6.27M | $3.35M | $2.90M | $3.15M | $3.01M | $2.77M | $3.97M | $7.69M | $3.84M | $2.16M | $2.03M | $- | $- | $- |
| Short Term Debt | $550.00K | $395.00K | $700.00K | $465.00K | $1.30M | $10.35M | $729.00K | $711.00K | $697.00K | $684.00K | $670.00K | $1.59M | $2.00M | $- | $- | $- |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $1.00K | $- | $- | $- |
| Deferred Revenue | $4.44M | $4.07M | $3.66M | $3.07M | $2.51M | $3.68M | $4.29M | $5.33M | $6.44M | $- | $5.00M | $-3.16M | $5.54M | $- | $- | $- |
| Other Current Liabilities | $6.08M | $7.03M | $3.88M | $3.53M | $4.50M | $4.30M | $3.83M | $3.26M | $-2.92M | $-6.93M | $15.19M | $-3.45M | $8.21M | $136.83K | $194.89K | $174.47K |
| Total Current Liabilities | $16.21M | $16.22M | $14.50M | $10.42M | $11.21M | $21.47M | $11.86M | $12.06M | $1.74M | $1.44M | $19.70M | $306.54K | $12.24M | $136.83K | $194.89K | $174.47K |
| Long Term Debt | $1.69M | $1.44M | $1.10M | $1.16M | $1.04M | $1.12M | $10.87M | $11.03M | $11.17M | $11.32M | $11.46M | $5.84M | $3.67M | $- | $- | $- |
| Deferred Revenue Non-Current | $- | $11.44M | $12.65M | $13.87M | $14.92M | $13.85M | $13.50M | $13.20M | $13.10M | $- | $16.45M | $- | $16.86M | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $-13.87M | $-14.92M | $- | $- | $- | $-24.28M | $- | $- | $- | $51.45M | $- | $- | $- |
| Other Non-Current Liabilities | $25.32M | $- | $- | $- | $- | $266.00K | $213.00K | $249.00K | $-5.57M | $-5.72M | $165.94M | $-244.00K | $-34.06M | $5.60M | $5.60M | $5.60M |
| Total Non-Current Liabilities | $27.01M | $12.88M | $13.75M | $15.02M | $15.96M | $15.23M | $24.58M | $24.47M | $5.60M | $5.60M | $193.85M | $5.60M | $72.52M | $5.60M | $5.60M | $5.60M |
| Other Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $43.22M | $29.10M | $28.26M | $25.44M | $27.17M | $36.70M | $36.44M | $36.53M | $7.34M | $7.04M | $213.55M | $5.91M | $84.76M | $5.74M | $5.79M | $5.77M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $51.45M | $165.92M | $165.94M | $76.71M | $51.45M | $- | $- | $- |
| Common Stock | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $4.00K | $3.00K | $67.68M | $67.68M | $160.14M | $160.00M | $160.00M | $160.00M | $151.24M | $151.33M |
| Retained Earnings | $-309.88M | $-293.72M | $-278.30M | $-262.32M | $-248.85M | $-236.04M | $-222.72M | $-210.67M | $-6.95M | $-6.07M | $-179.70M | $-4.38M | $-166.13M | $-3.85M | $-373.87K | $-281.54K |
| Accumulated Other Comprehensive Income Loss | $52.00K | $98.00K | $-23.00K | $-8.00K | $-10.00K | $-77.00K | $-96.00K | $-35.00K | $-8.00K | $0 | $-326.09M | $-236.71M | $-211.45M | $- | $- | $- |
| Other Total Stockholders Equity | $342.78M | $339.84M | $322.44M | $319.51M | $316.90M | $315.76M | $312.25M | $310.46M | $252.27M | $-98.25M | $575.29M | $487.48M | $357.80M | $- | $5.37M | $5.28M |
| Total Stockholders Equity | $32.96M | $46.22M | $44.12M | $57.19M | $68.04M | $79.66M | $89.44M | $99.75M | $60.73M | $61.61M | $-96.44M | $155.62M | $-71.23M | $156.15M | $156.24M | $156.33M |
| Total Equity | $32.96M | $46.22M | $44.12M | $57.19M | $68.04M | $79.66M | $89.44M | $99.75M | $60.73M | $61.61M | $-96.44M | $155.62M | $-71.23M | $156.15M | $156.24M | $156.33M |
| Total Liabilities and Stockholders Equity | $76.17M | $75.32M | $72.38M | $82.63M | $95.21M | $116.36M | $125.88M | $136.28M | $68.08M | $68.65M | $117.11M | $161.53M | $13.53M | $161.88M | $162.03M | $162.10M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $76.17M | $75.32M | $72.38M | $82.63M | $95.21M | $116.36M | $125.88M | $136.28M | $68.08M | $68.65M | $117.11M | $161.53M | $13.53M | $161.88M | $162.03M | $162.10M |
| Total Investments | $47.05M | $43.82M | $43.96M | $54.21M | $59.53M | $92.27M | $103.86M | $111.03M | $67.78M | $67.78M | $3.07M | $160.04M | $1.36M | $160.02M | $160.01M | $160.01M |
| Total Debt | $2.24M | $1.84M | $1.45M | $1.62M | $1.69M | $11.46M | $11.60M | $11.74M | $11.87M | $11.32M | $12.13M | $6.84M | $5.67M | $- | $- | $- |
| Net Debt | $-20.02M | $-23.77M | $-22.26M | $-21.70M | $-28.87M | $-7.62M | $-4.81M | $-6.96M | $11.69M | $10.58M | $-94.85M | $5.43M | $-4.26M | $-1.78M | $-1.91M | $-1.95M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-61.02M | $-49.12M | $-33.61M | $-23.01M | $-21.36M |
| Depreciation and Amortization | $308.00K | $287.00K | $222.00K | $181.00K | $137.00K |
| Deferred Income Tax | $- | $- | $-3.63M | $288.00K | $- |
| Stock Based Compensation | $10.62M | $7.62M | $3.41M | $302.00K | $221.00K |
| Change in Working Capital | $- | $-3.31M | $-451.00K | $2.60M | $-8.12M |
| Accounts Receivables | $22.00K | $-3.00K | $25.00K | $47.00K | $-79.00K |
| Inventory | $-28.00K | $131.00K | $-208.00K | $1.00K | $-26.00K |
| Accounts Payables | $2.97M | $145.00K | $183.00K | $1.08M | $-2.61M |
| Other Working Capital | $- | $-3.58M | $-451.00K | $1.47M | $-5.41M |
| Other Non Cash Items | $-457.00K | $-1.61M | $4.77M | $217.00K | $2.93M |
| Net Cash Provided by Operating Activities | $-50.56M | $-46.13M | $-29.29M | $-19.43M | $-26.18M |
| Investments in Property Plant and Equipment | $-289.00K | $-78.00K | $-591.00K | $-274.00K | $-539.00K |
| Acquisitions Net | $-602.00K | $- | $-29.06M | $-13.29M | $-27.50M |
| Purchases of Investments | $-72.65M | $-142.03M | $-63.53M | $-213.00K | $-15.62M |
| Sales Maturities of Investments | $86.63M | $152.80M | $92.59M | $13.50M | $43.13M |
| Other Investing Activities | $- | $- | $-63.53M | $13.29M | $27.50M |
| Net Cash Used for Investing Activities | $13.09M | $10.69M | $-64.12M | $13.02M | $26.97M |
| Debt Repayment | $- | $-10.85M | $3.55M | $-4.00M | $10.00M |
| Common Stock Issued | $352.00K | $254.00K | $109.83M | $- | $162.29M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $29.17M | $57.06M | $-10.13M | $7.00K | $- |
| Net Cash Used Provided by Financing Activities | $29.17M | $46.22M | $103.26M | $-3.99M | $10.00M |
| Effect of Forex Changes on Cash | $- | $- | $11.43M | $- | $- |
| Net Change in Cash | $-8.30M | $10.78M | $18.03M | $-10.40M | $10.78M |
| Cash at End of Period | $22.26M | $30.56M | $19.78M | $9.94M | $20.34M |
| Cash at Beginning of Period | $30.56M | $19.78M | $1.75M | $20.34M | $9.56M |
| Operating Cash Flow | $-50.56M | $-46.13M | $-29.29M | $-19.43M | $-26.18M |
| Capital Expenditure | $-289.00K | $-78.00K | $-591.00K | $-274.00K | $-539.00K |
| Free Cash Flow | $-50.85M | $-46.20M | $-29.88M | $-19.70M | $-26.72M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-16.16M | $-15.43M | $-15.98M | $-13.46M | $-12.82M | $-13.32M | $-12.05M | $-10.94M | $-9.75M | $-685.79K | $-7.85M | $-5.73M | $-88.01K | $-5.26M | $-6.16M | $-3.54M |
| Depreciation and Amortization | $84.00K | $76.00K | $74.00K | $74.00K | $72.00K | $71.00K | $73.00K | $71.00K | $70.00K | $54.00K | $50.00K | $48.00K | $48.00K | $46.00K | $44.00K | $43.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-1.08M | $-293.00K | $31.00K | $280.00K | $-1.87M | $-2.28M | $-33.00K | $365.00K | $- | $- | $- | $- |
| Stock Based Compensation | $2.90M | $2.36M | $2.76M | $2.59M | $919.00K | $3.51M | $1.71M | $1.49M | $863.00K | $2.22M | $257.00K | $70.00K | $39.00K | $67.00K | $135.00K | $61.00K |
| Change in Working Capital | $- | $-1.24M | $3.07M | $-1.83M | $-116.00K | $613.00K | $612.00K | $-4.42M | $94.00K | $241.93K | $-565.00K | $-265.00K | $63.21K | $-72.00K | $-113.00K | $179.00K |
| Accounts Receivables | $38.00K | $-35.00K | $-13.00K | $32.00K | $-13.00K | $85.00K | $-95.00K | $20.00K | $- | $-16.00K | $-1.00K | $42.00K | $13.00K | $28.00K | $-40.00K | $46.00K |
| Inventory | $60.00K | $-164.00K | $45.00K | $31.00K | $-8.00K | $41.00K | $54.00K | $44.00K | $54.00K | $-197.00K | $-101.00K | $36.00K | $61.00K | $-80.00K | $-11.00K | $31.00K |
| Accounts Payables | $-712.00K | $4.96M | $- | $-1.28M | $1.47M | $758.00K | $1.38M | $-3.46M | $- | $213.00K | $-234.00K | $373.00K | $- | $- | $- | $- |
| Other Working Capital | $4.85M | $-6.00M | $3.04M | $-1.90M | $-95.00K | $-271.00K | $-728.00K | $-1.02M | $40.00K | $241.93K | $-229.00K | $-716.00K | $63.21K | $-20.00K | $-62.00K | $102.00K |
| Other Non Cash Items | $-369.00K | $523.00K | $-132.00K | $2.19M | $2.05M | $-867.00K | $-867.00K | $-865.00K | $1.85M | $-127.62K | $173.00K | $187.00K | $-4.03K | $388.00K | $1.68M | $-2.33M |
| Net Cash Provided by Operating Activities | $-13.54M | $-13.70M | $-10.21M | $-13.11M | $-10.97M | $-10.28M | $-10.49M | $-14.38M | $-8.74M | $-571.49K | $-7.96M | $-5.32M | $-28.84K | $-4.83M | $-4.41M | $-5.59M |
| Investments in Property Plant and Equipment | $-106.00K | $-68.00K | $-107.00K | $-8.00K | $3.00K | $-19.00K | $-27.00K | $-35.00K | $-54.00K | $-224.00K | $-266.00K | $-47.00K | $-124.00K | $-53.00K | $- | $-97.00K |
| Acquisitions Net | $-602.00K | $- | $- | $- | $-33.15M | $-12.97M | $-64.20M | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $-20.27M | $-9.99M | $-18.65M | $-23.74M | $-3.96M | $-38.52M | $-56.05M | $-43.49M | $-63.32M | $- | $-208.00K | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $17.23M | $10.61M | $29.18M | $29.61M | $37.11M | $51.49M | $64.20M | $- | $- | $92.59M | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $5.87M | $33.15M | $12.97M | $64.20M | $-43.49M | $-63.32M | $224.00K | $-208.00K | $- | $-213.00K | $6.33M | $6.33M | $840.00K |
| Net Cash Used for Investing Activities | $-3.75M | $557.00K | $10.42M | $5.86M | $33.15M | $12.95M | $8.12M | $-43.53M | $-63.38M | $92.59M | $-474.00K | $-47.00K | $-337.00K | $6.28M | $6.33M | $743.00K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $4.55M | $-1.00M | $-1.00M | $-1.00M | $-1.00M | $-1.00M |
| Common Stock Issued | $352.00K | $-189.00K | $171.00K | $18.00K | $153.00K | $4.00K | $86.00K | $11.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $-109.83M | $-92.59M | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $13.95M | $15.04M | $171.00K | $18.00K | $-10.70M | $4.00K | $86.00K | $56.82M | $-5.09M | $-2.50M | $81.53M | $25.76M | $7.00K | $- | $- | $- |
| Net Cash Used Provided by Financing Activities | $13.95M | $15.04M | $171.00K | $18.00K | $-10.70M | $4.00K | $86.00K | $56.82M | $-5.09M | $-92.59M | $86.08M | $24.76M | $-993.00K | $-1.00M | $-1.00M | $-1.00M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $-8.18M | $-9.41M | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-3.34M | $1.89M | $389.00K | $-7.24M | $11.48M | $2.67M | $-2.29M | $-1.09M | $-77.21M | $-571.49K | $77.64M | $19.39M | $-28.84K | $448.00K | $925.00K | $-5.84M |
| Cash at End of Period | $22.26M | $25.61M | $23.71M | $23.32M | $30.56M | $19.08M | $16.41M | $18.70M | $19.78M | $735.22K | $106.97M | $29.33M | $1.75M | $15.87M | $15.43M | $14.50M |
| Cash at Beginning of Period | $25.61M | $23.71M | $23.32M | $30.56M | $19.08M | $16.41M | $18.70M | $19.78M | $97.00M | $1.31M | $29.33M | $9.94M | $1.78M | $15.43M | $14.50M | $20.34M |
| Operating Cash Flow | $-13.54M | $-13.70M | $-10.21M | $-13.11M | $-10.97M | $-10.28M | $-10.49M | $-14.38M | $-8.74M | $-571.49K | $-7.96M | $-5.32M | $-28.84K | $-4.83M | $-4.41M | $-5.59M |
| Capital Expenditure | $-106.00K | $-68.00K | $-107.00K | $-8.00K | $3.00K | $-19.00K | $-27.00K | $-35.00K | $-54.00K | $-224.00K | $-266.00K | $-47.00K | $-124.00K | $-53.00K | $- | $-97.00K |
| Free Cash Flow | $-13.64M | $-13.77M | $-10.31M | $-13.12M | $-10.97M | $-10.30M | $-10.52M | $-14.42M | $-8.80M | $-795.49K | $-8.23M | $-5.37M | $-152.84K | $-4.88M | $-4.41M | $-5.68M |
Orchestra BioMed Holdings Dividends
Explore Orchestra BioMed Holdings's dividend history, including dividend yield, payout ratio, and historical payments.
Orchestra BioMed Holdings News
Read the latest news about Orchestra BioMed Holdings, including recent articles, headlines, and updates.
Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update
NEW HOPE, Pa., March 31, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2024 financial results and provided a fourth quarter business update.
Orchestra BioMed to Present at Upcoming Investor Conferences
NEW HOPE, Pa., Feb. 20, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at multiple upcoming investor conferences.
Orchestra BioMed Appoints Vivek Reddy, M.D. as Executive Chairman of the BACKBEAT Study Steering Committee and Chairman of Bioelectronic Therapies Scientific Advisory Board
NEW HOPE, Pa., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of Vivek Reddy, M.D., as Executive Chairman of the Company's BACKBEAT Study Steering Committee and Chairman of its Bioelectronic Therapies Scientific Advisory Board. In these roles, Dr. Reddy will provide critical leadership in continuing to execute the BACKBEAT global pivotal study and further develop scientific evidence and clinical value for the Company's bioelectronic therapies portfolio.
Orchestra BioMed Announces Data Demonstrating Favorable Impact of AVIM Therapy on Diastolic Dysfunction, a Key Driver of Heart Failure Progression, will be Presented as Late-Breaking Science at the THT 2025 Conference
NEW HOPE, Pa., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced a late-breaking oral presentation of data on the benefits of atrioventricular interval modulation (“AVIM”) therapy on patients with diastolic dysfunction at the Technology and Heart Failure Therapeutics (“THT”) 2025 Conference in Boston, Massachusetts. The retrospective analysis of data from the MODERATO II study demonstrated that AVIM therapy significantly improved echocardiographic (“Echo”) markers of diastolic dysfunction, an important component in the development of heart failure, in hypertensive patients.
Orchestra BioMed Announces Appointment of Former Medtronic SVP of Corporate Development Christopher Cleary to Board of Directors
NEW HOPE, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of Christopher Cleary to its Board of Directors as an independent member, effective as of January 30, 2025. Mr. Cleary brings over three decades of experience in corporate development, mergers, acquisitions, strategic investments and structured R&D collaborations, having significantly impacted the medical technology industry through his strategic leadership and visionary approach.
Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference
NEW HOPE, Pa., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at the Piper Sandler 36th Annual Healthcare Conference being held in New York, NY from December 3-5, 2024.
Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update
NEW HOPE, Pa., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its third quarter 2024 financial results and provided a business update.
Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update
NEW HOPE, Pa., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its second quarter 2024 financial results and provided a business update.
Orchestra BioMed Holdings, Inc. (OBIO) Loses -25.35% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Orchestra BioMed Holdings, Inc. (OBIO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Wall Street Analysts Believe Orchestra BioMed Holdings, Inc. (OBIO) Could Rally 102.61%: Here's is How to Trade
The average of price targets set by Wall Street analysts indicates a potential upside of 102.6% in Orchestra BioMed Holdings, Inc. (OBIO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Orchestra BioMed Holdings, Inc. (OBIO) Stock Jumps 7.3%: Will It Continue to Soar?
Orchestra BioMed Holdings, Inc. (OBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Does Orchestra BioMed Holdings, Inc. (OBIO) Have the Potential to Rally 135.64% as Wall Street Analysts Expect?
The consensus price target hints at a 135.6% upside potential for Orchestra BioMed Holdings, Inc. (OBIO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Orchestra BioMed to Participate in Jefferies Global Healthcare Conference
NEW HOPE, Pa., May 22, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at the Jefferies Global Healthcare Conference being held in New York, NY, June 4-6, 2024.
Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update
NEW HOPE, Pa., May 13, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its first quarter 2024 financial results and provided a business update.
Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents
NEW HOPE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the patent estate related to AVIM Therapy has reached 110 patents worldwide. The most recent patent was issued today, April 30, 2024.
Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
NEW HOPE, Pa., March 27, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its full year 2023 financial results and provided a fourth quarter business update.
Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors
NEW HOPE, Pa., March 26, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the appointment of David Pacitti to its Board of Directors, effective as of March 26, 2024. Mr. Pacitti is currently the President of Siemens Medical Solutions USA, Inc. and Head of the Americas, Siemens Healthineers. Prior to joining Siemens Healthineers, he was Division Vice President of U.S. Commercial Operations, Sales, and Marketing at Abbott Vascular, overseeing the company's business in North America. As a member of the Senior Executive Staff, he worked with the CEO, CFO, and Research & Development team on business development initiatives and played pivotal roles in key launches, including Abbott Vascular's first drug-eluting stent and structural heart franchise.
Orchestra BioMed to Participate in Upcoming Investor Conferences
NEW HOPE, Pa., March 07, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced that company management will present and be available for one-on-one meetings at multiple conferences throughout March 2024.
Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients
NEW HOPE, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the presentation of new clinical data from a pressure-volume (“PV”) loop study of atrioventricular interval modulation (“AVIM”) therapy (also known as BackBeat CNT™) in pacemaker-indicated patients with uncontrolled hypertension despite the use of antihypertensive medication. These data demonstrate the favorable impact of AVIM therapy compared to standard right ventricular (RV) pacing on systolic blood pressure and overall cardiac function when delivered using both conduction system andstandard pacing lead locations. The PV loop study was conducted at Na Homolce Hospital in Prague by Prof. Petr Neužil, M.D. and the data were featured in an oral presentation at the Technology and Heart Failure Therapeutics (“THT”) 2024 Meeting by Prof. Karl-Heinz Kuck, M.D., Medical Director at LANS Cardio Hamburg.
Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients
NEW HOPE, Pa., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today announced the first patient was randomized in the BACKBEAT pivotal study in late December 2023. The BACKBEAT pivotal study will evaluate the efficacy and safety of atrioventricular interval modulation (“AVIM”) therapy (also known as BackBeat CNT™), for the treatment of pacemaker-indicated patients with uncontrolled hypertension despite the use of antihypertensive medications.
Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update
NEW HOPE, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today reported its third quarter 2023 financial results and provided a business update.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for OBIO.